More news from ANCHOR: Focus on women with high triglycerides
This sub analysis from the ANCHOR study showed that treatment with 4 g/day icosapent ethyl, a pure prescription eicosapentaenoic acid ethyl ester, showed benefit in women with type 2 diabetes mellitus (T2DM) and elevated triglycerides (TGs). The ANCHOR trial randomized 702 statin-treated patients (73% with diabetes; 39% women) at increased cardiovascular risk with elevated TGs (200-499 mg/dL) despite controlled low-density lipoprotein cholesterol (LDL-C, 40-99 mg/dL) to treatment with icosapent ethyl 2 g/day, 4 g/day, or placebo. This post hoc analysis focused on 146 women with T2DM (mean age 62 years) randomized to icosapent ethyl 4 g/day (n = 74) or placebo (n = 72). In this group, icosapent ethyl significantly reduced TGs (by 21.5%; p < 0.0001) without increasing LDL-C, and also had favourable effects on other potentially atherogenic lipids, lipoproteins, and inflammatory parameters versus placebo. Treatment was also well tolerated. These findings are relevant in the context of the ongoing Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial (REDUCE-IT) cardiovascular outcomes trial.
Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR Trial Subanalysis.
Brinton EA, Ballantyne CM, Guyton JR et al.